Provid Pharma

Executive Summary

Provid Pharmaceuticals is a privately held biotechnology company pioneering a novel approach to treating autoimmune diseases through selective Major Histocompatibility Complex (MHC) class II inhibition. Founded in 2014 and headquartered in San Diego, the company leverages its proprietary platform to design genetically targeted small molecule drugs that disrupt specific antigen presentation to T-cells. This mechanism aims to provide a more precise and safer alternative to broad immunosuppression, potentially reducing off-target effects and improving patient outcomes. By targeting MHC class II, Provid's approach addresses the root cause of autoimmune pathologies—the inappropriate activation of T-cells by self-antigens—offering a differentiated strategy in a competitive landscape.

Upcoming Catalysts (preview)

• H2 2026Preclinical Efficacy Data for PV-3212 in MS Models60% success
• Q1 2027Initiation of IND-Enabling Toxicology Studies70% success